Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

MD Anderson scientists show why some brain cancer patients develop resistance to treatments

MD Anderson scientists show why some brain cancer patients develop resistance to treatments

New cancer drug enters phase I clinical trials in humans

New cancer drug enters phase I clinical trials in humans

Researchers one step closer to understanding development of glioblastoma

Researchers one step closer to understanding development of glioblastoma

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Researchers create new intraoperative probe for detecting cancer cells

Researchers create new intraoperative probe for detecting cancer cells

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

Drugs designed to target NHE9 protein could help fight glioblastoma

Drugs designed to target NHE9 protein could help fight glioblastoma

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

New study links cell communication pathway to common brain tumors found in children

New study links cell communication pathway to common brain tumors found in children

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

New study identifies three genes that enable glioblastoma to recur, progress after radiation therapy

New study identifies three genes that enable glioblastoma to recur, progress after radiation therapy

Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

Manchester researcher discover novel way to eradicate cancer stem cells

Manchester researcher discover novel way to eradicate cancer stem cells

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Researchers identify new target that could lead to potential therapies for GBM

Researchers identify new target that could lead to potential therapies for GBM

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.